A phase II-a, open-label, randomized study of JX-594 (thymidine kinase-deleted vaccinia virus plus GM-CSF) administered by intratumoral injection in patients with unresectable primary hepatocellular carcinoma.
Phase of Trial: Phase II
Latest Information Update: 02 Jan 2018
At a glance
- Drugs Pexastimogene devacirepvec (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Jennerex
- 02 Jan 2018 According to a GC Pharma media release, Green Cross Corporation rebrands itself to GC Pharma.
- 12 Feb 2013 Results were published in Nature Medicine, according to a Jennerex media release.
- 03 Jan 2013 Planned end date changed from 1 Dec 2011 to 1 Feb 2013 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History